Tech Company Financing Transactions
Accro Bioscience Funding Round
On 5/19/2026, Accro Bioscience raised $50 million in Series C funding from OrbiMed, Cenova Capital and LAV Fund.
Transaction Overview
Company Name
Announced On
5/19/2026
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the Phase IIb clinical trial of AC-101, a RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&I diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Unit E37, North Tower, Building A1, BioBay, No. 218 Xinghu S
Suzhou, Jiangsu, 215123
China
Suzhou, Jiangsu, 215123
China
Phone
Website
Email Address
Overview
Accropeutics has fostered a robust portfolio of innovative compounds spanning from lead optimization to clinical development. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns more than 20 patents issued in major markets including the US, the EU, China, Japan, and Korea.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xiaohu Zhang
Chief Medical Officer
Ki Rito
Co-Founder
Sudan He
Vice President
Sanmao Kang
Vice President
Haikuo Ma
VP - Bus. Development
Kenneth Gao
Browse more venture capital transactions:
Prev: 5/19/2026: Nourish venture capital transaction
Next: 5/19/2026: Century Health venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs